J 2023

16S rRNA gene primer choice impacts off-target amplification in human gastrointestinal tract biopsies and microbiome profiling

DEISSOVÁ, Tereza; Martina ZAPLETALOVÁ; Lumír KUNOVSKÝ; Radek KROUPA; Tomáš GROLICH et al.

Basic information

Original name

16S rRNA gene primer choice impacts off-target amplification in human gastrointestinal tract biopsies and microbiome profiling

Authors

DEISSOVÁ, Tereza; Martina ZAPLETALOVÁ; Lumír KUNOVSKÝ; Radek KROUPA; Tomáš GROLICH; Zdeněk KALA; Petra BOŘILOVÁ LINHARTOVÁ and Jan LOCHMAN

Edition

SCIENTIFIC REPORTS, England, NATURE PORTFOLIO, 2023, 2045-2322

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

Germany

Confidentiality degree

is not subject to a state or trade secret

References:

Marked to be transferred to RIV

Yes

RIV identification code

RIV/00216224:14110/23:00132245

Organization

Lékařská fakulta – Repository – Repository

EID Scopus

Keywords in English

ESOPHAGEAL MICROBIOTA; REVEALS; SAMPLE

Links

EF17_043/0009632, research and development project. LM2018140, research and development project. NU20-03-00126, research and development project. 857560, interní kód Repo. RECETOX RI, large research infrastructures. NCMG II, large research infrastructures.
Changed: 16/10/2024 00:50, RNDr. Daniel Jakubík

Abstract

In the original language

16S rRNA amplicon sequencing or, more recently, metatranscriptomic analysis are currently the only preferred methods for microbial profiling of samples containing a predominant ratio of human to bacterial DNA. However, due to the off-target amplification of human DNA, current protocols are inadequate for bioptic samples. Here we present an efficient, reliable, and affordable method for the bacteriome analysis of clinical samples human DNA content predominates. We determined the microbiota profile in a total of 40 human biopsies of the esophagus, stomach, and duodenum using 16S rRNA amplicon sequencing with the widely used 515F-806R (V4) primers targeting the V4 region, 68F-338R primers and a modified set of 68F-338R (V1-V2M) primers targeting the V1-V2 region. With the V4 primers, on average 70% of amplicon sequence variants (ASV) mapped to the human genome. On the other hand, this off-target amplification was absent when using the V1-V2M primers. Moreover, the V1-V2M primers provided significantly higher taxonomic richness and reproducibility of analysis compared to the V4 primers. We conclude that the V1-V2M 16S rRNA sequencing method is reliable, cost-effective, and applicable for low-bacterial abundant human samples in medical research.

Files attached